Tarlatamab Mechanism and DeLLphi-305 Trial Design

Dr. Sands discusses tarlatamab's unique mechanism as a bispecific T-cell engager linking DLL3 on tumor cells to CD3 on T cells, creating an antigen-directed immune response distinct from other therapeutic approaches. He characterizes the second-line DeLLphi-304 trial as establishing an entirely new paradigm, representing the only example of one drug outperforming others in SCLC's second-line setting across PFS, OS, tolerability, and symptom improvement.

The phase 1b DeLLphi-303 trial evaluated tarlatamab with PD-L1 inhibition in maintenance, showing remarkable 82% 1-year OS compared to IMforte's 56% 1-year OS, generating substantial enthusiasm for the ongoing phase 3 DeLLphi-305 trial comparing durvalumab alone versus durvalumab plus tarlatamab in maintenance following carboplatin, etoposide, and durvalumab induction.

Regarding what would change practice, Dr. Sands emphasizes that tarlatamab's toxicity profile, primarily cytokine release syndrome and ICANS occurring mainly with initial doses, plus taste alterations, is quite favorable long-term, meaning even modest efficacy improvements would represent meaningful advances. He's particularly interested in OS data and duration of therapy beyond PFS metrics, having observed that patients often remain on treatment longer than PFS suggests due to oligo-progression patterns, indicating PFS curves may not fully capture true clinical benefit in this novel therapeutic class.